UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June 5, 2006
Date of Report (Date of earliest event reported)
--------------------------------------------------------------------------------
ANTIGENICS INC
(Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------
DELAWARE 000-29089 06-1562417
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
630 Fifth Avenue, Suite 2100
New York, NY 10111 10111
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On June 5, 2006, Antigenics Inc. announced updated findings from its
Phase 3 clinical trial of the company's investigational cancer vaccine
Oncophage(R) (vitespen; formerly HSPPC-96) in metastatic melanoma. The
full text of the press release issued in connection with the
announcement is being furnished as Exhibit 99.1 to this current report
on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated June 5, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: June 5, 2006
By: /s/ Garo H. Armen, Ph.D.
------------------------------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated June 5, 2006